Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel
Kane Biotech has received Health Canada approval for its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device. This regulatory milestone enables the company to immediately begin marketing and selling the product in the Canadian market. The approval represents a significant step in Kane Biotech's strategic execution plan.
Kane Biotech ha ricevuto l'approvazione da parte di Health Canada per il suo gel antimicrobico re vyve™ come Dispositivo Medico di Classe 2. Questo traguardo normativo consente all'azienda di iniziare immediatamente a commercializzare e vendere il prodotto nel mercato canadese. L'approvazione rappresenta un passo significativo nel piano di esecuzione strategica di Kane Biotech.
Kane Biotech ha recibido la aprobación de Health Canada para su gel antimicrobiano re vyve™ como Dispositivo Médico de Clase 2. Este hito regulatorio permite a la empresa comenzar a comercializar y vender el producto en el mercado canadiense de inmediato. La aprobación representa un paso significativo en el plan de ejecución estratégica de Kane Biotech.
케인 바이오텍은 리바이브™ 항균 상처 젤에 대해 캐나다 보건부의 2등급 의료기기 승인을 받았습니다. 이 규제 이정표는 회사가 캐나다 시장에서 즉시 제품을 마케팅하고 판매를 시작할 수 있게 합니다. 이 승인은 케인 바이오텍의 전략적 실행 계획에 있어 중요한 단계입니다.
Kane Biotech a reçu l'approbation de Santé Canada pour son gel antimicrobien re vyve™ en tant que Dispositif Médical de Classe 2. Ce jalon réglementaire permet à l'entreprise de commencer immédiatement à commercialiser et à vendre le produit sur le marché canadien. L'approbation représente une étape significative dans le plan d'exécution stratégique de Kane Biotech.
Kane Biotech hat die Genehmigung von Health Canada für sein revyve™ antimikrobielles Wundgel als Medizinprodukt der Klasse 2 erhalten. Dieser regulatorische Meilenstein ermöglicht es dem Unternehmen, sofort mit dem Marketing und dem Verkauf des Produkts auf dem canadischen Markt zu beginnen. Die Genehmigung stellt einen bedeutenden Schritt im strategischen Ausführungsplan von Kane Biotech dar.
- Received Health Canada approval for revyve™ Antimicrobial Wound Gel
- Immediate authorization to market and sell in Canadian market
- Product classification as Class 2 Medical Device achieved
- None.
WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device.
This approval allows the Company to immediately start promoting and selling this product in Canada.
“We are excited to bring this much needed product to Canada,” said Marc Edwards, President & CEO. “Congratulations to the Kane Biotech team for achieving this important milestone and continue to execute on our strategic plan.”
About Kane Biotech
Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane has a portfolio of biotechnologies, intellectual property (66 patents and patents pending as well as trade secrets and trademarks) and products developed by Kane's own biofilm research expertise and acquired from leading research institutions. DispersinB®, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. Kane is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information:
| Marc Edwards | Ray Dupuis |
| Chief Executive Officer | Chief Financial Officer |
| Kane Biotech Inc | Kane Biotech Inc |
| medwards@kanebiotech.com | rdupuis@kanebiotech.com |
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to Kane’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of Kane to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by Kane with applicable securities regulatory authorities, available at www.sedarplus.ca. Kane cautions that the foregoing list of factors that may affect future results is not exhaustive.
FAQ
What regulatory approval did Kane Biotech (KNBIF) receive in November 2024?
Can Kane Biotech (KNBIF) sell revyve™ Antimicrobial Wound Gel in Canada?
What classification did Health Canada give to Kane Biotech's (KNBIF) revyve™ wound gel?
